1. Home
  2. Clinical Journal of Oncology Nursing

Clinical Journal of Oncology Nursing

  • Pharmacokinetics: Unique Challenges in Blood Monitoring for Oncology Nurses

    Chemotherapy
    Stem Cell Transplant
    CJON 2019, 23(2), 191-196 DOI: 10.1188/19.CJON.191-196

    Background: Pharmacokinetics (PK) is the study of the absorption, distribution, metabolism, and excretion of drugs.

    Read this article

  • CAR T-Cell Therapy: Update on the State of the Science

    Immunotherapy
    Clinical Trials
    CJON 2019, 23(2), 6-12 DOI: 10.1188/19.CJON.S1.6-12

    Background: Chimeric antigen receptor (CAR) T-cell therapy leverages the power of the patient’s own immune system by serving as a bridge to connect genetically modified T cells to the surface antigens of tumor cells based on targeted ligands.

    Read this article

  • Pediatric Survivorship: Considerations Following CAR T-Cell Therapy

    Pediatrics
    Immunotherapy
    Leukemia
    CJON 2019, 23(2), 35-41 DOI: 10.1188/19.CJON.S1.35-41

    Background: This article presents an overview of pediatric relapsed and refractory acute lymphoblastic leukemia (ALL) and chimeric antigen receptor (CAR) T-cell therapy in pediatric patients.

    Read this article
Go to Current Issue

Advanced Print Exclusives

CJON 2019, A1-A7 DOI:

Personal Protective Equipment: Evaluating Usage Among Inpatient and Outpatient Oncology Nurses

Background: Chemotherapy agents have long been considered hazardous, and safety for healthcare providers when administering these drugs is a primary...
Read More

Journal Club/Open Access

CJON 2019, 23(2), 149-155 DOI: 10.1188/19.CJON.149-155

Symptom Distress: Implementation of Palliative Care Guidelines to Improve Pain, Fatigue, and Anxiety in Patients With Advanced Cancer

Background: The integration of palliative care into standard oncology care is supported by research to improve quality of life and symptom distress...
Read MoreMore Open Access

Resources

Communication
CJON 2019, 23(2), 123 DOI: 10.1188/19.CJON.123
Innovation and Invention
Being a transplant to the Golden State of California for the past 31 years, I have had the privilege to live in arguably one of the most vibrant and...
Read MoreMore Like This
Immunotherapy
CJON 2019, 23(2), 20-26 DOI: 10.1188/19.CJON.S1.20-26
Building a Program: Implications for Infrastructure, Nursing Education, and Training for CAR T-Cell Therapy
Background: Chimeric antigen receptor (CAR) T-cell therapy program development has regulatory demands and unique operational processes that vary...
Read MoreMore Like This
Pediatrics
CJON 2019, 23(2), 35-41 DOI: 10.1188/19.CJON.S1.35-41
Pediatric Survivorship: Considerations Following CAR T-Cell Therapy
Background: This article presents an overview of pediatric relapsed and refractory acute lymphoblastic leukemia (ALL) and chimeric antigen receptor (...
Read MoreMore Like This
Advocacy
CJON 2019, 23(2), 217-219 DOI: 10.1188/19.CJON.217-219
340B Drug Pricing Program: The Expansion and Its Effect on Cancer Care
The 340B Drug Pricing Program is a complex federal program that is intended to provide financial relief to hospitals that provide care to greater...
Read MoreMore Like This
Palliative Care
CJON 2019, 23(2), 149-155 DOI: 10.1188/19.CJON.149-155
Symptom Distress: Implementation of Palliative Care Guidelines to Improve Pain, Fatigue, and Anxiety in Patients With Advanced Cancer
Background: The integration of palliative care into standard oncology care is supported by research to improve quality of life and symptom distress...
Read MoreMore Like This
Treatment Decision Making
CJON 2019, 23(2), 212-216 DOI: 10.1188/19.CJON.212-216
Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura
The thrombopoietin receptor agonists, eltrombopag and romiplostim, are second-line agents used to treat chronic immune thrombocytopenia purpura (ITP...
Read MoreMore Like This